A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

Trial Profile

A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Jul 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms ASPIRE
  • Sponsors Amgen; Onyx Pharmaceuticals
  • Most Recent Events

    • 12 Jul 2017 According to an Amgen media release, data from this trial will be submitted to a future medical conference, for publication, and to regulatory agencies worldwide to support a potential label update.
    • 12 Jul 2017 Results from final analysis of this trial published in an Amgen media release.
    • 25 Jun 2017 Results assessing relative progression free survival over time of novel triplet regimens using patient data from ELOQUENT-2, ASPIRE, and TOURMALINE-MM1 trial, presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top